---
document_datetime: 2025-12-02 05:36:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/proquad.html
document_name: proquad.html
version: success
processing_time: 0.3706295
conversion_datetime: 2025-12-27 21:52:17.27464
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# ProQuad

[RSS](/en/individual-human-medicine.xml/66343)

##### Authorised

This medicine is authorised for use in the European Union

measles, mumps, rubella and varicella vaccine (live) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on ProQuad](#news-on)
- [More information on ProQuad](#more-information-on-proquad-677)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

ProQuad is a vaccine against measles, mumps, rubella, and varicella (chickenpox).

ProQuad is given to children from 12 months of age to help protect them against measles, mumps, rubella, and chickenpox. ProQuad may also be given to children from 9 months of age in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common.

Expand section

Collapse section

## ProQuad contains attenuated (weakened) viruses for the diseases. How is ProQuad used?

ProQuad is injected into a muscle or under the skin, preferably in the thigh in younger children and in the upper arm in older children and adults. Rarely, in a child with a bleeding disorder, the vaccine is injected under the skin to prevent excessive bleeding.

For children above 12 months of age, one ProQuad injection is sufficient for protection against measles, mumps and rubella. To protect against chickenpox, a second injection needs to be given 1 to 3 months after the first one; this can be done either by giving a second dose of ProQuad or by giving a vaccine that only protects against chickenpox.

Children between 9 and 12 months of age should receive a second dose at least 3 months after the first dose for adequate protection against measles and chickenpox.

ProQuad can only be obtained with a prescription. It is used according to official recommendations, including recommendations about the number of doses and the interval between them.

## How does ProQuad work?

ProQuad contains weakened forms of the viruses that cause measles, mumps, rubella and chickenpox. When a person receives the vaccine, it triggers an immune response against the weakened viruses. Later, when the person comes into contact with the actual viruses, the immune system recognises them and is already prepared to attack the viruses and so protects the person from the disease.

## What benefits of ProQuad have been shown in studies?

Because ProQuad contains well known weakened viruses, which are used in other vaccines, the company presented data from vaccines that are already on the market. Five main studies were carried out in 6,987 healthy children (aged 12 to 23 months). In these studies, after one dose, the response rates in children (measuring how well the immune system had responded to the viruses) were: 98% for measles, 96 to 99% for mumps, 99% for rubella and 91% for chickenpox. After the second dose, the rates were around 99% for measles, 100% for mumps, 98% for rubella, and 99% for chickenpox.

Another study in 1,620 children from 9 to 12 months of age showed that, after two doses of ProQuad given 3 months apart, the immune response against mumps, rubella and chickenpox in children who received the first dose at 9 months of age was comparable with those who received the first dose at 12 months of age. However, children who received the first dose at 9 months of age had a lower immune response against measles.

## What are the risks associated with ProQuad?

The most common side effects with ProQuad (which may affect more than 1 in 10 people) are fever, and pain and erythema (redness) at the site of injection. For the full list of side effects of ProQuad, see the package leaflet.

ProQuad must not be used in children who are hypersensitive (allergic) to any chickenpox vaccine or measles, mumps or rubella vaccine, or to any of the other ingredients including neomycin. It must not be used in children who have severely weakened immune systems. It must also not be used in a pregnant woman. For the full list of restrictions, see the package leaflet.

## Why has ProQuad been approved?

The European Medicines Agency decided that ProQuad's benefits are greater than its risks and it can be authorised for use in the EU in children above 12 months of age and in certain situations from 9 months of age, noting that a second vaccination against chickenpox should be given for full protection against the disease.

The Agency also recommended that the vaccine be authorised in children from 9 to 12 months of age only in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common.

## Other information about ProQuad

ProQuad received a marketing authorisation valid throughout the EU on 6 April 2006.

ProQuad : EPAR - Medicine overview

Reference Number: EMA/433362/2020

English (EN) (135.22 KB - PDF)

**First published:** 02/06/2006

**Last updated:** 08/10/2020

[View](/en/documents/overview/proquad-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-774)

български (BG) (155.37 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/bg/documents/overview/proquad-epar-medicine-overview_bg.pdf)

español (ES) (135.23 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/es/documents/overview/proquad-epar-medicine-overview_es.pdf)

čeština (CS) (163.5 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/cs/documents/overview/proquad-epar-medicine-overview_cs.pdf)

dansk (DA) (134.98 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/da/documents/overview/proquad-epar-medicine-overview_da.pdf)

Deutsch (DE) (137.98 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/de/documents/overview/proquad-epar-medicine-overview_de.pdf)

eesti keel (ET) (129.27 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/et/documents/overview/proquad-epar-medicine-overview_et.pdf)

ελληνικά (EL) (158.05 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/el/documents/overview/proquad-epar-medicine-overview_el.pdf)

français (FR) (135.9 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/fr/documents/overview/proquad-epar-medicine-overview_fr.pdf)

hrvatski (HR) (151.15 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/hr/documents/overview/proquad-epar-medicine-overview_hr.pdf)

italiano (IT) (121.34 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/it/documents/overview/proquad-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.36 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/lv/documents/overview/proquad-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (151.72 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/lt/documents/overview/proquad-epar-medicine-overview_lt.pdf)

magyar (HU) (151.87 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/hu/documents/overview/proquad-epar-medicine-overview_hu.pdf)

Malti (MT) (154.95 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/mt/documents/overview/proquad-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.58 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/nl/documents/overview/proquad-epar-medicine-overview_nl.pdf)

polski (PL) (152.93 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/pl/documents/overview/proquad-epar-medicine-overview_pl.pdf)

português (PT) (122.89 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/pt/documents/overview/proquad-epar-medicine-overview_pt.pdf)

română (RO) (150.05 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/ro/documents/overview/proquad-epar-medicine-overview_ro.pdf)

slovenčina (SK) (146.12 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/sk/documents/overview/proquad-epar-medicine-overview_sk.pdf)

slovenščina (SL) (147.03 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/sl/documents/overview/proquad-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.17 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/fi/documents/overview/proquad-epar-medicine-overview_fi.pdf)

svenska (SV) (123.34 KB - PDF)

**First published:**

02/06/2006

**Last updated:**

08/10/2020

[View](/sv/documents/overview/proquad-epar-medicine-overview_sv.pdf)

ProQuad : EPAR - Risk-management-plan summary

English (EN) (1.6 MB - PDF)

**First published:** 26/06/2020

[View](/en/documents/rmp-summary/proquad-epar-risk-management-plan-summary_en.pdf)

## Product information

ProQuad : EPAR - Product Information

English (EN) (441.46 KB - PDF)

**First published:** 12/08/2009

**Last updated:** 25/09/2025

[View](/en/documents/product-information/proquad-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-345)

български (BG) (387.76 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/bg/documents/product-information/proquad-epar-product-information_bg.pdf)

español (ES) (486.16 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/es/documents/product-information/proquad-epar-product-information_es.pdf)

čeština (CS) (456.27 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/cs/documents/product-information/proquad-epar-product-information_cs.pdf)

dansk (DA) (463.12 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/da/documents/product-information/proquad-epar-product-information_da.pdf)

Deutsch (DE) (507.93 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/de/documents/product-information/proquad-epar-product-information_de.pdf)

eesti keel (ET) (471.83 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/et/documents/product-information/proquad-epar-product-information_et.pdf)

ελληνικά (EL) (417.65 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/el/documents/product-information/proquad-epar-product-information_el.pdf)

français (FR) (484.9 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/fr/documents/product-information/proquad-epar-product-information_fr.pdf)

hrvatski (HR) (454.53 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/hr/documents/product-information/proquad-epar-product-information_hr.pdf)

íslenska (IS) (475.12 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/is/documents/product-information/proquad-epar-product-information_is.pdf)

italiano (IT) (499.4 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/it/documents/product-information/proquad-epar-product-information_it.pdf)

latviešu valoda (LV) (420.49 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/lv/documents/product-information/proquad-epar-product-information_lv.pdf)

lietuvių kalba (LT) (428.6 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/lt/documents/product-information/proquad-epar-product-information_lt.pdf)

magyar (HU) (503.24 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/hu/documents/product-information/proquad-epar-product-information_hu.pdf)

Malti (MT) (494.02 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/mt/documents/product-information/proquad-epar-product-information_mt.pdf)

Nederlands (NL) (486.21 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/nl/documents/product-information/proquad-epar-product-information_nl.pdf)

norsk (NO) (456.11 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/no/documents/product-information/proquad-epar-product-information_no.pdf)

polski (PL) (481.1 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/pl/documents/product-information/proquad-epar-product-information_pl.pdf)

português (PT) (466.05 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/pt/documents/product-information/proquad-epar-product-information_pt.pdf)

română (RO) (448.55 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/ro/documents/product-information/proquad-epar-product-information_ro.pdf)

slovenčina (SK) (456.74 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/sk/documents/product-information/proquad-epar-product-information_sk.pdf)

slovenščina (SL) (442.84 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/sl/documents/product-information/proquad-epar-product-information_sl.pdf)

Suomi (FI) (488.95 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/fi/documents/product-information/proquad-epar-product-information_fi.pdf)

svenska (SV) (461.29 KB - PDF)

**First published:**

12/08/2009

**Last updated:**

25/09/2025

[View](/sv/documents/product-information/proquad-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000300468 24/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

ProQuad : EPAR - All Authorised presentations

English (EN) (67.43 KB - PDF)

**First published:** 24/08/2006

**Last updated:** 26/06/2020

[View](/en/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-0)

български (BG) (74.39 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/bg/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.41 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/es/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_es.pdf)

čeština (CS) (70.42 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/cs/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (62.71 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/da/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (63.9 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/de/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (65.43 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/et/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.86 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/el/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_el.pdf)

français (FR) (66.53 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/fr/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (66.56 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/hr/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (87.97 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/is/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_is.pdf)

italiano (IT) (65.72 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/it/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (78.32 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/lv/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.89 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/lt/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (72.31 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/hu/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (147.22 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/mt/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (69.25 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/nl/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (61.09 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/no/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.16 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/pl/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.83 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/pt/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.54 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/ro/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.16 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/sk/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (74.8 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/sl/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (60.27 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/fi/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.85 KB - PDF)

**First published:**

24/08/2006

**Last updated:**

26/06/2020

[View](/sv/documents/all-authorised-presentations/proquad-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine ProQuad Active substance virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella International non-proprietary name (INN) or common name measles, mumps, rubella and varicella vaccine (live) Therapeutic area (MeSH)

- Chickenpox
- Rubella
- Measles
- Mumps
- Immunization

Anatomical therapeutic chemical (ATC) code J07BD54

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age.

ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.

## Authorisation details

EMA product number EMEA/H/C/000622 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Marketing authorisation issued 05/04/2006 Revision 36

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

ProQuad : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.73 KB - PDF)

**First published:** 19/08/2025

**Last updated:** 25/09/2025

[View](/en/documents/procedural-steps-after/proquad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

ProQuad : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (464.46 KB - PDF)

**First published:** 12/08/2009

**Last updated:** 04/07/2025

[View](/en/documents/procedural-steps-after/proquad-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

ProQuad-H-C-PSUSA-00001936-202409 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (131.56 KB - PDF)

**First published:** 04/07/2025

[View](/en/documents/scientific-conclusion/proquad-h-c-psusa-00001936-202409-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

ProQuad-H-C-622-P46-0054 : EPAR - Assessment Report

Adopted

Reference Number: EMA/246946/2015

English (EN) (968.2 KB - PDF)

**First published:** 15/04/2015

**Last updated:** 15/04/2015

[View](/en/documents/variation-report/proquad-h-c-622-p46-0054-epar-assessment-report_en.pdf)

ProQuad-H-C-622-P46-0038 : EPAR - Assessment Report

Adopted

Reference Number: EMA/479847/2014

English (EN) (697.85 KB - PDF)

**First published:** 22/10/2014

**Last updated:** 22/10/2014

[View](/en/documents/variation-report/proquad-h-c-622-p46-0038-epar-assessment-report_en.pdf)

ProQuad-H-C-622-P46-0053 : EPAR - Assessment Report

Adopted

Reference Number: EMA/655900/2014

English (EN) (100.71 KB - PDF)

**First published:** 22/10/2014

**Last updated:** 22/10/2014

[View](/en/documents/variation-report/proquad-h-c-622-p46-0053-epar-assessment-report_en.pdf)

ProQuad-H-C-662-P46-0041 : EPAR - Assessment Report

Adopted

Reference Number: EMA/640073/2014

English (EN) (281.59 KB - PDF)

**First published:** 17/10/2014

**Last updated:** 17/10/2014

[View](/en/documents/variation-report/proquad-h-c-662-p46-0041-epar-assessment-report_en.pdf)

ProQuad-H-C-622-P46-0026 : EPAR - Assessment Report

Adopted

Reference Number: EMA/639014/2014

English (EN) (257.6 KB - PDF)

**First published:** 16/10/2014

**Last updated:** 16/10/2014

[View](/en/documents/variation-report/proquad-h-c-622-p46-0026-epar-assessment-report_en.pdf)

ProQuad-H-C-622-X-0068 : EPAR - Assessment Report - Extension

Adopted

English (EN) (306.97 KB - PDF)

**First published:** 12/02/2014

**Last updated:** 12/02/2014

[View](/en/documents/variation-report/proquad-h-c-622-x-0068-epar-assessment-report-extension_en.pdf)

Proquad-H-C-622-A20-0060 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/78633/2013

English (EN) (125.06 KB - PDF)

**First published:** 27/03/2013

**Last updated:** 27/03/2013

[View](/en/documents/variation-report/proquad-h-c-622-a20-0060-epar-assessment-report-article-20_en.pdf)

ProQuad-H-C-622-II-0055 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/164243/2013

English (EN) (368.45 KB - PDF)

**First published:** 27/03/2013

**Last updated:** 27/03/2013

[View](/en/documents/variation-report/proquad-h-c-622-ii-0055-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

ProQuad : EPAR - Procedural steps taken before authorisation

English (EN) (97.06 KB - PDF)

**First published:** 02/06/2006

**Last updated:** 02/06/2006

[View](/en/documents/procedural-steps/proquad-epar-procedural-steps-taken-authorisation_en.pdf)

ProQuad : EPAR - Scientific Discussion

English (EN) (334.88 KB - PDF)

**First published:** 02/06/2006

**Last updated:** 02/06/2006

[View](/en/documents/scientific-discussion/proquad-epar-scientific-discussion_en.pdf)

#### News on ProQuad

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2012) 14/12/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 March 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-march-2012) 16/03/2012

#### More information on ProQuad

- [Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines](/en/medicines/human/referrals/monovalent-multivalent-measles-mumps-rubella-varicella-vaccines)

ProQuad: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission

English (EN) (531.82 KB - PDF)

**First published:** 14/12/2012

**Last updated:** 14/12/2012

[View](/en/documents/referral/proquad-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 25/09/2025

## Share this page

[Back to top](#main-content)